12 2 STA T .30 3 6PUBLIC LA W 110 – 31 4— AU G .14 , 200 8ofmin o r i typ op ula tion s an d r ec ommendations for minimi z in g suc h ris k s
- (2)
recommendations for pu b lic outreach , a w areness, and pre v ention campaigns specifically aimed at racial minority populations; and ( 3 ) recommendations for education initiatives that may reduce statistical disparities .SEC.108 . PROHIB I T IO N ONS AL EO F CERTAIN PRO DU CTS CONTAININ G SPECIFIED PHTHALATES. (a) PROHIB I T IO N ON TH ESAL EO FC ERTAIN PRO DUC T S CON - TAININ G PHTHALATES. —B eginning on the date that is 180 days after the date of enactment of this A ct, it shall be unlawful for any person to manufacture for sale, offer for sale, distribute in commerce, or import into the U nited States any children ’ s toy or child care article that contains concentrations of more than 0.1 percent of di-(2-ethylhe x yl) phthalate ( DEH P), dibutyl phthalate (DBP), or benzyl butyl phthalate (BBP). (b) PROHIBITION ON THE SALE OF ADDITIONAL PRODUCTS CON- TAINING CERTAIN PHTHALATES.— (1) I NTERI MP ROHIBITION.—Beginning on the date that is 180 days after the date of enactment of this Act and until a final rule is promulgated under paragraph (3), it shall be unlawful for any person to manufacture for sale, offer for sale, distribute in commerce, or import into the United States any children’s toy that can be placed in a child’s mouth or child care article that contains concentrations of more than 0.1 per- cent of diisononyl phthalate (DI N P), diisodecyl phthalate (DIDP), or di-n-octyl phthalate (Dn O P). (2) CHRONIC HA Z ARD AD V ISOR Y PANEL.— (A) APPOINTMENT.—Not earlier than 180 days after the date of enactment of this Act, the Commission shall begin the process of appointing a Chronic Hazard Advisory Panel pursuant to the procedures of section 28 of the Con- sumer Product Safety Act (1 5 U.S.C. 20 7 7) to study the effects on children’s health of all phthalates and phthalate alternatives as used in children’s toys and child care arti- cles. (B) E X AMINATION.— T he panel shall, within 18 months after its appointment under subparagraph (A), complete an examination of the full range of phthalates that are used in products for children and shall— (i) examine all of the potential health effects (including endocrine disrupting effects) of the full range of phthalates; (ii) consider the potential health effects of each of these phthalates both in isolation and in combination with other phthalates; (iii) examine the likely levels of children’s, preg- nant women’s, and others’ exposure to phthalates, based on a reasonable estimation of normal and foreseeable use and abuse of such products; (iv) consider the cumulative effect of total exposure to phthalates, both from children’s products and from other sources, such as personal care products; (v) review all relevant data, including the most recent, best-available, peer-reviewed, scientific studies Deadlin e s.Ef fe ct i v e date. Effective date. 15USC20 5 7 c.
�
